Actinium Ac 225 Lintuzumab

RADIATION3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Acute Myeloid LeukemiaRecurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaRecurrent WHO Grade 4 GliomaRefractory Myelodysplastic Syndrome

Phase 1

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

SuspendedNCT06802523

National Cancer Institute (NCI)Acute Myeloid Leukemia

Start: 2026-04-21End: 2028-12-31Target: 53Updated: 2026-04-03

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

SuspendedNCT06888323

National Cancer Institute (NCI)Refractory Myelodysplastic Syndrome

Start: 2026-04-27End: 2027-12-31Target: 30Updated: 2026-04-03

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Not yet recruitingNCT07422363

National Cancer Institute (NCI)Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma

Start: 2026-06-28End: 2027-02-28Target: 30Updated: 2026-04-03